Top Ten most popular articles on this week

pharmafile | September 7, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, MHRA, Trump, brexit, research, scandal, top 10 

Brexit took the top two spots this week after it was revealed that the EMA has awarded Britain’s MHRA just two contracts this year, while GSK complained that Brexit will cost them $100 million. Meanwhile scandals have soured the first week of September as Sanofi settled charges of corruption with a $25 million dollar payment to the US while Dutch doctors campaigned against the price hiking Italian firm Leadiant Biosciences.

However in what is great news for young people suffering from leukaemia, Novartis’ CAR T therapy Kymriah, a one-time cancer treatment that uses a patient’s own immune cells in combatting cancer was accepted by NICE and thus will become available on the NHS.

To find out more, check out this week’s Top 10 most popular articles on now!

10. AI used to forecast cancer progression

A team of scientists at the Institute of Cancer Research in London and the University of Edinburgh have developed an artificial intelligence that is able to predict the ways in which cancers will progress and evolve. The technique may help doctors design personalised treatments.

9. Sanofi to pay $25m over Kazakhstan and Middle East corruption allegations

French pharma giant Sanofi will pay more than $25 million to settle corruption charges related to their subsidiaries in Kazakhstan and the Middle East.

8. Novartis sells key Sandoz US portfolios to Aurobindo for $1bn

Novartis has revealed it is to sell the dermatology and generic US oral solids portfolios of its generics arm Sandoz to Indian firm Aurobindo Pharma for $1 billion, in a move the company says will enable it to better achieve “sustainable and profitable growth in the US over the long-term”.

7. FDA turns to real-world evidence to improve regulatory process

The FDA is to incorporate real-world data elements to a greater degree into its regulatory decision-making framework in a bid to “answer questions that are relevant to broader patient populations or treatment settings where information may not be captured through traditional clinical trials.”

6. Novartis’ CAR T therapy Kymriah to become available on the NHS

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was revealed that the cancer treatment will be offered to children and young adults up to the age of 25 years old with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

5. Dutch doctors resist pharma firm’s 500-fold price hike

A group of Dutch doctors and health advocates are taking action against the Italian pharmaceutical firm Leadiant Biosciences who have increased the price of a lifesaving drug by 500 times its original price.

4. Trump administration resists WHO efforts to tackle antimicrobial resistance

The Trump administration is in the process of drafting an alternative to the World Health Organization’s guidelines on the use of antimicrobial drugs in food producing animals. In resisting the WHO guidelines, which are intended to combat antimicrobial resistance, the move seems to benefit agribusiness.

3. GSK to axe 650 positions across US workforce

GlaxoSmithKline has announced its intention to cut 650 employees from its current US workforce, with the cutbacks coming as part of a global restructuring effort announced in July earlier this year.

2. Pfizer says Brexit will cost the company $100 million

The US multinational Pfizer has said that Brexit will cost the company $100 million in spend associated with the transference of product and testing licenses to other countries, alterations to clinical trial management procedures and other preventative measures.

1. MHRA loses EMA contracts in wake of Brexit

The EMA has awarded Britain’s regulatory body the MHRA just two contracts this year, as the European agency suggested that the uncertainty surrounding Brexit has made Britain off limits for new regulatory contracts.

Related Content

Is the pharmaceutical sector prepared to face a titanium dioxide ban?

Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the …

NICE recommends Otsuka’s Lupkynis (voclosporin) in combination treatment for active lupus nephritis

Otsuka Pharmaceuticals has announced that the National Institutes for Health and Care Excellence (NICE) has …


New targeted lung cancer treatment coming to UK under MHRA scheme

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for …

Latest content